title: Ninth Biannual Report of the Cochrane Haematological Malignancies Group--focus on hematopoietic growth factors.
authors.affiliation: Cochrane Haematological Malignancies Group, Department 1 of Internal Medicine, University Hospital of Cologne, Kerpener St 62, 50924 Cologne, Germany. nicole.skoetz@uk-koeln.de
authors.forename: Nicole
authors.initials: N
authors.lastname: Skoetz
authors.forename: Olaf
authors.initials: O
authors.lastname: Weingart
authors.forename: Ina
authors.initials: I
authors.lastname: Monsef
authors.forename: Kathrin
authors.initials: K
authors.lastname: Bauer
authors.forename: Corinne
authors.initials: C
authors.lastname: Brillant
authors.forename: Christine
authors.initials: C
authors.lastname: Herbst
authors.forename: Sabine
authors.initials: S
authors.lastname: Kluge
authors.forename: Andreas
authors.initials: A
authors.lastname: Engert
mesh_terms: D000747:Anemia, Hypochromic / Q000139:chemically induced / Q000188:drug therapy* / Q000209:etiology* / Q000517:prevention & control; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D002985:Clinical Protocols; D000068256:Darbepoetin alfa; D003627:Data Interpretation, Statistical; D004921:Erythropoietin / Q000008:administration & dosage / Q000819:agonists / Q000031:analogs & derivatives; D005260:Female; D000069585:Filgrastim; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000188:drug therapy; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006098:Granulocytes / Q000187:drug effects; D006397:Hematinics / Q000627:therapeutic use*; D019337:Hematologic Neoplasms / Q000188:drug therapy; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000188:drug therapy; D008223:Lymphoma / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D015337:Multicenter Studies as Topic; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy* / Q000401:mortality; D009503:Neutropenia / Q000188:drug therapy / Q000209:etiology; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D011087:Polycythemia Vera / Q000188:drug therapy; D011092:Polyethylene Glycols; D016032:Randomized Controlled Trials as Topic / Q000379:methods / Q000592:standards; D011994:Recombinant Proteins; D012107:Research Design; D016019:Survival Analysis; D013920:Thrombocythemia, Essential / Q000188:drug therapy; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D006397:Hematinics; D016298:Hematopoietic Cell Growth Factors; D016756:Immunoglobulins, Intravenous; D010975:Platelet Aggregation Inhibitors; D011994:Recombinant Proteins; C103998:epoetin beta; D004921:Erythropoietin; D016179:Granulocyte Colony-Stimulating Factor; D000068256:Darbepoetin alfa; C455861:pegfilgrastim; D011092:Polyethylene Glycols; D000069585:Filgrastim